GRDN Guardian Pharmacy Services, Inc.
Retail-Drug Stores and Proprietary Stores · NYSE · SEC CIK 1802255 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.9%
TTM net income YoY85.8%
TTM EPS YoY84.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin22.4%
Operating margin6.5%
Net margin5.1%
FCF margin—
EBITDA margin8.1%
Returns
ROE33.2%
ROA17.0%
ROIC (approx.)46.2%
Asset turnover3.30x
Leverage & solvency
Liabilities / assets43.1%
Debt / equity0.00x
Current ratio1.65x
Interest coverage145.28x
Cash quality & payout
Operating cash flow / net income1.53x
Accruals ratio-8.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $371.07M | $351.77M | $336.60M | $397.62M | $377.43M | $344.33M | $329.31M | $338.57M |
| Cost of revenue | $285.85M | $271.72M | $260.29M | $312.11M | $302.71M | $276.19M | $264.96M | $271.46M |
| Gross profit | $85.22M | $80.04M | $76.31M | $85.50M | $74.72M | $68.15M | $64.35M | $67.10M |
| SG&A expense | $60.16M | $59.40M | $58.63M | $54.74M | $58.37M | $55.57M | $51.34M | $50.35M |
| Operating income | $25.06M | $20.64M | $17.68M | $30.76M | $16.35M | $12.58M | $13.01M | $16.75M |
| Interest expense | $177,000 | $154,000 | $154,000 | $163,000 | $160,000 | $172,000 | $170,000 | $421,000 |
| Pretax income | $25.98M | $29.79M | $18.29M | $31.10M | $16.63M | $12.59M | $13.11M | $16.22M |
| Income tax | $6.86M | $7.67M | $4.75M | $9.83M | $7.04M | $3.76M | $3.83M | $4.38M |
| Net income | $18.68M | $21.87M | $13.29M | $20.92M | $9.82M | $9.03M | $9.45M | $11.94M |
| EBITDA | $31.00M | $26.45M | $23.65M | $36.50M | $22.19M | $18.07M | $18.27M | $21.91M |
| EPS (basic) | 0.29 | — | — | — | 0.16 | — | — | — |
| EPS (diluted) | 0.29 | — | — | — | 0.15 | — | — | — |
| Weighted avg. shares (diluted) | 63.92M | — | — | — | 63.43M | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $119.66M | $89.81M | $64.89M | $65.62M | $36.49M | $18.82M | $14.00M | $4.66M |
| Receivables | $107.68M | $103.77M | $111.70M | $101.61M | $106.19M | $94.12M | $97.41M | $97.15M |
| Inventory | $57.05M | $50.44M | $47.16M | $43.36M | $47.86M | $44.16M | $43.43M | $40.55M |
| Current assets | $294.82M | $254.67M | $235.18M | $221.63M | $198.28M | $170.46M | $166.04M | $151.99M |
| PP&E, net | $57.42M | $56.53M | $56.62M | $55.52M | $56.12M | $54.43M | $51.47M | $49.88M |
| Goodwill | $81.95M | $79.74M | $79.74M | $79.74M | $79.57M | $76.16M | $69.30M | $69.30M |
| Intangibles | $20.84M | $16.62M | $17.48M | $18.48M | $18.91M | $17.59M | $14.08M | $14.91M |
| Total assets | $491.78M | $443.58M | $426.94M | $412.66M | $390.04M | $356.33M | $334.00M | $320.81M |
| Current liabilities | $179.09M | $154.04M | $160.54M | $160.70M | $161.95M | $143.99M | $145.30M | $144.12M |
| Long-term debt | — | — | — | $0 | — | — | — | $0 |
| Total debt | — | — | — | $0 | — | — | — | $0 |
| Total liabilities | $212.06M | $185.94M | $194.52M | $194.73M | $194.54M | $176.66M | $170.78M | $170.83M |
| Shareholders' equity | $267.24M | $245.61M | $220.89M | $205.76M | $183.76M | $169.56M | $156.09M | $142.67M |
| Net debt | — | — | — | -$65.62M | — | — | — | -$4.66M |
| Cash flow statement | ||||||||
| Operating cash flow | $43.37M | $30.02M | $6.06M | $34.60M | $28.17M | $19.94M | $17.55M | $22.34M |
| Capital expenditure | — | — | — | $495,000 | $4.00M | — | — | $2.25M |
| Free cash flow | — | — | — | $34.10M | $24.17M | — | — | $20.09M |
| Investing cash flow | -$10.90M | -$4.31M | -$4.75M | -$4.71M | -$8.97M | -$13.00M | -$5.54M | -$6.62M |
| Financing cash flow | -$2.62M | -$805,000 | -$2.04M | -$758,000 | -$1.53M | -$2.11M | -$2.67M | -$48.27M |
| Depreciation & amortization | $5.93M | $5.81M | $5.98M | $5.74M | $5.84M | $5.49M | $5.27M | $5.15M |
| Stock-based compensation | $2.73M | $2.93M | $1.86M | $1.08M | $4.36M | $4.45M | $3.97M | $3.46M |
| Share buybacks | — | — | — | — | $0 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 12 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.